%{{tag.tag}} {{articledata.title}} {{moment(articledata.cdate)}} @{{articledata.company.replace(" ","")}} comment It should be a big session for a %Healthcare company based out of New Hampshire following an announcement that the company will be acquired in an all-stock deal valued at roughly $103 million, according to a press release. Seeing that the company closed Tuesday’s session with a market cap of around $53 million, it’s no wonder that traders rushed to snatch up shares of %iCad Inc. (Nasdaq: $ICAD ) following the announcement, with traders currently bid for the micro cap at $3.23/share (+67.36% implied open for sellers) at the time of writing. Keep an eye on this one! icad Inc provides cancer detection, radiation therapy and workflow solutions, primarily computer-aided detection and workflow solutions for breast, prostate and colorectal cancers. Its products include powerlook tomo detection, powerlook density assessment, and vera look. The firm has also developed a technology namely Xoft Axxent electronic brachytherapy system used in the treatment of non-melanoma skin cancer, early-stage breast cancer, and gynecological cancers.